San Francisco-based Sempre Health, a startup tackling medication adherence and affordability, has closed an $8 million Series A round spearheaded by Rethink Impact. Social Capital and other investors also participated.
The new funding will be used to grow Sempre’s relationships with health plans and to make Sempre available to more patients.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Via email, Sempre Health CEO Anurati Mathur explained the company’s approach.
“Sempre Health offers dynamic discounts and SMS-based engagement to patients via their health plans,” she said.
Thus, patients don’t have to pay as much when they make better decisions about their health, such as filling prescriptions on time. The ultimate goal is to improve medication adherence as well as patient engagement.
From the non-patient perspective, Sempre does two things.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
It enrolls pharma manufacturers, who then add their medications to the platform. It also signs up insurers, who make Sempre’s programs available to their members. Insurers are also able to pick which medications are part of the Sempre programs by selecting them from the list of medicines that pharma manufacturers added.
Mathur touched on why the investors in the Series A make good partners.
“Healthcare is a meaningful but highly regulated and fragmented industry. Not every investor is up to the challenge,” she said. “What our investors have in common with us is the belief that you can do well while doing good.”
Going forward, the San Francisco startup seeks to make more medications available on its platform. This, Mathur said, requires continuing to improve its platform and develop partnerships.
In April, Sempre launched a collaboration with Novo Nordisk in hopes of incentivizing diabetes patients to have better medication adherence. The alliance will narrow in on diabetes medication from Novo Nordisk, and the goal is to onboard 10,000 patients in 2018.
Last summer, the California company began a pilot with a large provider-led health plan in Pennsylvania. Sempre declined to name the insurer. The pilot started with heart patients.
Photo: TAW4, Getty Images
